Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. On December 31, 2025, January 5, 2026 and January 6, 2026, Brainstorm Cell Therapeutics Inc. (the “ Company ”) enter
Unregistered Sales of Equity Securities. The Notes, and the shares of the Company’s common stock issuable upon conversion of the Notes, if any, were or will be
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Securities Purchase Agreement, dated December 31, 2025, by and between the Company